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Rich new resource
Half of human melanomas harbor the oncogenic 
BRAFV600E allele, yet target genes and pathways cooperate 
with this allele in tumor development, as evidenced by 
frequent relapse following initial response to the selec-
tive BRAF inhibitor PLX-4032 (vemurafenib). Mann and 
colleagues recently utilized a Sleeping Beauty (SB) trans-
poson mutagenesis screen in Braf-mutant mice to uncov-
er 1,232 recurring mutated candidate cancer genes from 
70 SB-driven melanomas, and the vast majority of these 
identified genes were putative haploinsufficient tumor 
suppressor genes. The identified genes are more highly 
connected via functional molecular links than  anticipated 
and function in large signaling networks that can be 
deregulated at multiple levels. Moreover, this study iden-
tified CEP350, which has been suggested to function in 
microtubule anchoring and nuclear hormone receptor 
signaling, as a new candidate human melanoma tumor 
suppressor gene. Overall, these studies reveal that SB 
drives melanoma development in these Braf-mutant mice 
and provide a rich new resource of candidate genes for 
melanoma progression and drug targeting. (Nat Genet 
47:486–95, 2015) Selected by T. Darling
Settle the source debate
Psoriasis is mediated by the proinflammatory cytokines 
IL-17 and IL-22, which are increased in serum and skin 
lesions of patients. The source of these cytokines in pso-
riasis has been a matter of debate, although IL-22 was 
believed to be derived from TH17, TH22, and Tc22 cells 
and IL-17 is thought to be derived from TH17 cells. Innate 
immune cells have been implicated as an additional source 
of IL-17 and IL-22, and mast cells (MCs) in particular have 
been found to produce IL-17 in psoriatic skin. To settle 
the debate about the sources of these cytokines, Mashiko 
and colleagues utilized a novel system to characterize 
inflammatory cells from biopsy specimens of psoriatic 
skin without expansion or stimulation. Human MCs were 
found to express IL-22 mRNA and protein at the single-cell 
level, and these cKit+FcεR1+ MCs serve as a predominant 
source of IL-22 in patients with psoriasis and in patients 
with atopic dermatitis. The skin MCs also serve as minor 
contributors of IL-17. Together, these findings suggest that 
MCs may be critical in the pathophysiology of chronic 
inflammatory skin disorders. (J Allergy Clin Immunol, pub-
lished online 16 March 2015; doi:10.1016/j.jaci.2015.01.033) 
Selected by J. T. Elder
Adipocyte expansion
Cells residing in the skin, including epithelial cells, MCs, 
and resident leukocytes, likely restrict the spread of 
microbial infectious agents preceding the recruitment 
of neutrophils and monocytes. Zhang and colleagues 
recently reported an expansion of the subcutaneous adi-
pose layer following exposure to Staphylococcus aureus 
skin infection. The adipocytes progressively increased in 
size following infection, and preadipocytes rapidly pro-
liferated. Both genetic and pharmacologic impairment 
of adipogenesis resulted in increased susceptibility to S. 
aureus skin infection at the injection site, highlighting the 
importance of this adipocyte expansion to control infec-
tion. Furthermore, increased production of the antimi-
crobial peptide cathelicidin by adipocytes was critical for 
host defense function because the cathelicidin gene was 
induced during adipocyte differentiation and inhibition 
of adipogenesis resulted in decreased cathelicidin expres-
sion. Therefore, local increase in subcutaneous adipocytes 
and increased production of an antimicrobial peptide by 
these cells serve as important host defense mechanisms 
during skin infections. (Science 347:67–71, 2015)
Selected by T. Schwarz
Catastrophe for a cure
Investigation of a case of spontaneous, durable, and com-
plete clinical remission of WHIM syndrome in a patient 
whose two daughters fulfilled the criteria for the disease 
revealed chromothriptic deletions of one copy of chromo-
some 2, including deletion of the disease allele CXCR4R334X. 
This fortuitous chromothripsis, which is a mechanism of 
genetic instability that is thought to occur all at once with-
in one cell, provided a “cure” for the patient’s clinical out-
come, despite continued mild hypogammaglobulinemia 
and deficiency of B and naive T cells. This event occurred 
in a single hematopoietic stem cell, which then selectively 
repopulated the myeloid lineage but not the lymphoid lin-
eage, repopulated the bone marrow, and restored normal 
immune function. These findings suggest that CXCR4 hap-
loinsufficiency may actually promote hematopoietic stem-
cell engraftment of bone marrow in transplant patients. 
(Cell 160:686–99, 2015) Selected by M. Amagai
Neoantigen cancer vaccination
Somatic mutations that are present in melanomas because 
of exposure to mutagens such as UVR may yield antigens 
that are viewed as foreign and thus stimulate the antitumor 
immune response. In a recent report in Science, Carreno 
and colleagues demonstrated that vaccination with high-
affinity, tumor-derived mutant peptides increases T-cell 
immunity that is directed at naturally occurring dominant 
tumor neoantigens and exposes previously undetected 
subdominant neoantigens, expanding the scope of the 
antitumor immune response. This vaccination strategy 
yielded a diverse neoantigen-specific T-cell receptor rep-
ertoire. Thus, vaccination directed at patient-specific 
tumor-encoded neoantigens increases the breadth of 
antitumor immunity and offers an exciting new avenue 
for exploration of personalized treatment for melanoma 
and other cancers. Furthermore, a therapeutic strategy 
involving treatment with checkpoint inhibitors such as 
ipilimumab in combination with neoantigen vaccines 
may improve clinical outcomes for melanoma patients. 
(Science 348:803–8, 2015) Selected by M. Amagai
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